About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Invitrogen and Clontech Settle Lengthy Patent Litigation | Main | The (As Yet) Unfulfilled Promise of Personalized Genomics »

May 31, 2007

FDA Grants Approval to UCB & Sanofi-Aventis Allergy Drug

    By Christopher P. Singer --

Ucb In a May 29, 2007 press release, sanofi-aventis and UCB announced that the FDA approved Xyzal® (active ingredient: levocetirizine dihydrochloride) a once-daily prescription antihistamine for the relief of seasonal and perennial allergic rhinitis, as well as for the treatment of chronic idiopathic urticaria (hives) in adults and in children age six and older.  UCB filed the new drug application (NDA) in July 2006 and researched the drug in a number of clinical trials.  Xyzal® was shown to reduce the severity of common symptoms associated with allergies, such as runny nose, itchy eyes, and sneezing.  In patients with hives, the drug was able to reduce the number, size, and itch associated with the hives.

In the fall of 2006, sanofi-aventis signed an agreement with UCB in which it agreed to launch and co-market and Xyzal®, which is expected to be ready for launch for the upcoming fall allergy season.

Sanofiaventis

Posted at 11:31 PM in Biotech/Pharma News |

Comments

The comments to this entry are closed.

October 2024

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Categories

Archives

More...